Health Care Services

Laboratory Corporation of America® Holdings (NYSE: LH) announced today the nationwide availability of a new FDA-approved diagnostic for melanoma patients. The drug ZelborafTM and the cobas® 4800 BRAF V600 Mutation Test companion diagnostic, both from Roche, were approved by the FDA on August 17...

Repros Therapeutics Inc. (Nasdaq: RPRX) today announced it believes that enough patients have enrolled in each of its three ongoing Androxal studies to provide statistically meaningful results for each trial. The Company expects to report top-line data for the three trials at the end of 2011. The...

Laboratory Corporation of America® Holdings (NYSE: LH) announced today that it has extended the term of its agreement with UnitedHealthcare Insurance Company, an affiliate of UnitedHealth Group Incorporated (NYSE: UNH) for an additional two years. The agreement, which was effective January 1, 2007...

LTX-Credence Corporation (NASDAQ: LTXC) fell 16.94% to $5.49 at 9:50 am. LTXC reported a 12% drop in its fiscal fourth-quarter earnings and issued a downbeat forecast for its first fiscal quarter. CardioNet Inc (NASDAQ: BEAT) shares lost 16.45% to $3.15. Analysts at Roth Capital lowered price...

Shares of LHC Group Inc (NASDAQ: LHCG) gained about 1.1% after the company announced that proven healthcare development executive Don Adam has joined the Company as senior vice president and chief development officer for home health and hospice services. Shares of SAIC Inc (NYSE: SAI) gained about...

LHC Group, Inc. (Nasdaq: LHCG) today announced that proven healthcare development executive Don Adam has joined the Company as senior vice president and chief development officer for home health and hospice services. Adam's credentials include more than a decade of post-acute healthcare...

HMS, a wholly owned subsidiary of HMS Holdings Corp. (NASDAQ: HMSY), announced today that is has been awarded a contract by the State of New Mexico, Human Services Department/Medical Assistance Division, to provide third party liability, program integrity, Recovery Audit Contractor, and revenue...

Gentiva Health Services, Inc. (Nasdaq: GTIV) announced today that it has agreed to sell its remaining equity stake in CareCentrix Holdings Inc.  The Company expects to realize net cash flow of $65 to $70 million as a result of the transaction. The Company will continue to hold a $25 million note...

Benchmark has published a research report on Bio-Reference Labs (NASDAQ: BRLI). In the report, Benchmark wrote, "Revenue in F3Q11 expanded 21.6% to $148.0 million, which exceeded the $146.3 million consensus and nearly met our $148.5 million forecast. Pro-forma EPS expanded 25.6% to $0.36, which...

Jefferies & Co. is out with a research report on Bio-Reference Labs (NASDAQ: BRLI) and is lowering its price target to $21 from $23, but is keeping its Hold rating on shares. In a note to clients, Jefferies & Co. writes, "While we applaud BRLI's strong Q3 performance, fundamentals don't...

Jefferies & Company has lowered the price target on Bio-Reference Labs (NASDAQ: BRLI) from $23 to $21 and maintains its Hold rating.

Insider Monkey follows hedge fund managers because they're the smartest investors around. They leave less to chance than do most investors. They go to great lengths to get an “edge” over ordinary investors. Hedge fund managers also have the resources to do extensive research on public companies and...

Landauer, Inc. (NYSE: LDR) today announced that its Board of Directors has appointed, Michael T. Leatherman, as the Company's Interim Chief Financial Officer, as well as its acting principal financial officer and principal accounting officer, effective September 9, 2011. Leatherman succeeds...

PDI, Inc. (Nasdaq: PDII) today announced that its seasonal sales services agreement with a Top 10 pharmaceutical company has been renewed for an additional season. The pharmaceutical company will continue to utilize PDI's Shared Sales team beginning in September 2011 through March 2012 to reach...

Piper Jaffray is out with its report today on Quest Diagnostics (NYSE: DGX), lowering its PT to $55 from $61. In its report, Piper Jaffray writes, "Given the recent concerns about the debt ceiling issue and potential Medicare cuts (copay for labs), we are reducing our price target to $55 from $61...